SCHEMBL7708221

SCHEMBL7708221

CC1Oc2ccc(C(Cc3ccc(S(C)(=O)=O)cc3)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.40
ALDH1A1 P00352 4/20 0.37
HPGD P15428 4/20 0.37
HTT P42858 4/20 0.37
NPSR1 Q6W5P4 4/20 0.37
PTPRB P23467 4/20 0.37
LMNA P02545 3/20 0.37
PKM P14618 3/20 0.37
HSD17B10 Q99714 3/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
AGTR1 P30556 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ALOX15 P16050 1/20 0.37
XBP1 P17861 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
JAK2 O60674 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7093832 0.91 PTPRB (0.37) ALDH1A1HPGDHTTNPSR1PTPRB
SCHEMBL7713294 0.90 PARP1 (0.42) PARP1ALDH1A1HPGDHTTNPSR1
SCHEMBL7713338 0.89 PARP1 (0.42) PARP1ALDH1A1HSD17B10TSHRTP53
SCHEMBL7708144 0.89 PARP1 (0.42) PARP1ALDH1A1HPGDHTTNPSR1
SCHEMBL7713374 0.89 PARP1 (0.50) PARP1ALDH1A1HPGDHTTNPSR1
SCHEMBL7711371 0.88 PARP1 (0.41) PARP1ALDH1A1HPGDHTTNPSR1
SCHEMBL7708029 0.87 PARP1 (0.41) PARP1ALDH1A1HPGDHTTNPSR1
SCHEMBL7708231 0.87 CA2 (0.39) PARP1
SCHEMBL7713423 0.85 PARP1 (0.41) PARP1ALDH1A1HSD17B10TSHRTP53
SCHEMBL7710382 0.85 PARP1 (0.40) PARP1HPGDRAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed